A recent review published in Science China Life Sciences by Professor Yan-Jiang Wang and colleagues explores why progress has been limited. The researchers argue that focusing on a single cause has not worked because Alzheimer’s is far more complex. It arises from the combined effects of amyloid-beta (Aβ) buildup, Tau protein tangles, genetic risk factors, aging-related changes, and broader health conditions. Because of this complexity, they suggest that future treatments must take a more comprehensive and coordinated approach.

Alzheimer’s Disease Involves Multiple Interconnected Factors

The review highlights several key areas that are reshaping how scientists understand Alzheimer’s.

Beyond Amyloid-Beta (Aβ)

Amyloid-beta has long been a central target in Alzheimer’s research, but treatments aimed only at this protein have produced limited results. Scientists are now paying closer attention to Tau hyperphosphorylation, a process that leads to the formation of neurofibrillary tangles and the loss of brain cells. Addressing both Aβ and Tau may be necessary to slow disease progression more effectively.

Genetic Risk and Emerging Gene Therapies

Genetics play a major role in determining Alzheimer’s risk. While APOE ε4 remains the most widely recognized genetic factor, researchers are identifying additional variants linked to specific populations. Advances in genome editing (CRISPR/Cas9) are also being explored as potential one-time treatments that could modify disease risk at its source.

Aging and Whole-Body Health Shape Alzheimer’s Progression

Aging as a Central Driver

Aging is the strongest risk factor for Alzheimer’s and involves a range of biological changes. These include declining mitochondrial function, the buildup of damaged cells, and increased DNA damage. The review points to “senolytic” therapies, which aim to remove aging glial cells, as a possible way to improve brain health and slow decline.

Systemic Health and the Gut-Brain Connection

Alzheimer’s is also influenced by conditions that affect the entire body. Issues such as insulin resistance, high blood pressure, and imbalances in gut bacteria can worsen disease processes. Researchers are investigating whether existing diabetes medications and therapies targeting the gut-brain axis could help reduce these effects.

Toward Integrated and Multi-Target Alzheimer’s Therapies

The authors emphasize the need to move away from “reductionist” thinking and toward “integrated strategies.” This shift involves developing treatments that target multiple aspects of the disease at once. It also includes using advanced laboratory models, such as human iPSC-derived organoids, to test new therapies more effectively. In addition, precision medicine approaches based on early biomarkers like plasma pTau217 could allow doctors to identify and treat Alzheimer’s earlier and more accurately.

“Success in defeating Alzheimer’s hinges on interdisciplinary collaboration and holistic innovation,” the authors conclude. Their findings outline a path forward, suggesting that with the right combination of strategies, Alzheimer’s could eventually become a manageable or even preventable condition rather than an inevitable decline.

“We were surprised to find that zeaxanthin, already known for its role in eye health, has a completely new function in boosting anti-tumor immunity,” said Jing Chen, PhD, Janet Davison Rowley Distinguished Service Professor of Medicine and senior author of the study. “Our study show that a simple dietary nutrient could complement and strengthen advanced cancer treatments like immunotherapy.”

How Zeaxanthin Activates Cancer-Fighting T Cells

The research builds on years of work from Chen’s lab exploring how nutrients shape immune responses. By analyzing a large library of nutrients found in blood, the team identified zeaxanthin as a compound that directly enhances the performance of CD8+ T cells. These immune cells play a central role in identifying and destroying cancer cells.

CD8+ T cells rely on a structure called the T-cell receptor (TCR) to detect abnormal cells. The researchers found that zeaxanthin helps stabilize the formation of this receptor complex when T cells encounter cancer. This leads to stronger internal signaling, which increases T-cell activation, boosts cytokine production, and improves the cells’ ability to kill tumors.

Boosting the Power of Immunotherapy

In mouse studies, adding zeaxanthin to the diet slowed tumor growth. The effect became even more pronounced when combined with immune checkpoint inhibitors – a type of immunotherapy that has transformed cancer treatment in recent years. Together, the combination produced stronger anti-tumor responses than immunotherapy alone.

The team also tested human T cells that had been engineered to target specific cancer markers. In laboratory experiments, zeaxanthin enhanced these cells’ ability to destroy melanoma, multiple myeloma, and glioblastoma cells.

“Our data show that zeaxanthin improves both natural and engineered T-cell responses, which suggests high translational potential for patients undergoing immunotherapies,” Chen said.

A Safe, Accessible Nutrient With Broad Potential

Zeaxanthin is already widely used as an over-the-counter supplement for eye health. It is naturally present in foods such as orange peppers, spinach, and kale. Because it is inexpensive, easy to obtain, and well tolerated, researchers believe it could be quickly tested as a complementary approach to cancer treatment.

The findings also highlight the broader importance of diet in immune health. In earlier work, Chen’s team identified trans-vaccenic acid (TVA), a fatty acid found in dairy and meat, as another compound that enhances T-cell function through a different pathway. Together, these discoveries suggest that nutrients from both plant and animal sources may work in complementary ways to support the immune system.

What Comes Next for Zeaxanthin in Cancer Care

While the results are promising, the researchers stress that the work is still in its early stages. Most of the evidence so far comes from laboratory experiments and animal models. Clinical trials will be needed to determine whether zeaxanthin can improve outcomes for people with cancer.

“Our findings open a new field of nutritional immunology that looks at how specific dietary components interact with the immune system at the molecular level,” Chen said. “With more research, we may discover natural compounds that make today’s cancer therapies more effective and accessible.”

The study, “Zeaxanthin augments CD8+ effector T cell function and immunotherapy efficacy,” was supported by grants from the National Institutes of Health, the Ludwig Center at the University of Chicago, and the Harborview Foundation Gift Fund.

Additional authors include Freya Zhang, Jiacheng Li, Rukang Zhang, Jiayi Tu, Zhicheng Xie, Takemasa Tsuji, Hardik Shah, Matthew Ross, Ruitu Lyu, Junko Matsuzaki, Anna Tabor, Kelly Xue, Chunzhao Yin, Hamed R. Youshanlouei, Syed Shah, Michael W. Drazer, Yu-Ying He, Marc Bissonnette, Jun Huang, Chuan He, Kunle Odunsi, and Hao Fan from the University of Chicago; Fatima Choudhry from DePaul University, Chicago; Yuancheng Li and Hui Mao from Emory University School of Medicine, Atlanta; Lei Dong from University of Texas Southwestern Medical Center, Dallas; and Rui Su from Beckman Research Institute, City of Hope, Duarte, CA.

Researchers at the University of Geneva (UNIGE) have developed a new approach that could change this. Using machine learning, they created the first detailed catalogue of all human gut bacteria at a level precise enough to reveal how different microbial subgroups function in the body. They then used this information to detect colorectal cancer based on bacteria found in simple stool samples, offering a non-invasive and low-cost alternative. The findings, published in Cell Host & Microbe, could also help scientists better understand how gut microbiota influences overall health and disease.

Why Better Screening Tools Are Needed

Many cases of colorectal cancer are diagnosed late, when treatment options are more limited. This highlights the urgent need for easier and less invasive screening methods, especially as cases continue to rise among younger adults for reasons that remain unclear.

Scientists have long known that gut microbiota plays a role in colorectal cancer. However, turning that knowledge into practical medical tools has been difficult. One major challenge is that different strains within the same bacterial species can behave very differently. Some may contribute to cancer development, while others have no effect at all.

Focusing on Microbiota Subspecies

“Instead of relying on the analysis of the various species composing the microbiota, which does not capture all meaningful differences, or of bacterial strains, which vary greatly from one individual to another, we focused on an intermediate level of the microbiota, the subspecies,” explains Mirko Trajkovski, full professor in the Department of Cell Physiology and Metabolism and in the Diabetes Centre at the UNIGE Faculty of Medicine, who led this research.

“The subspecies resolution is specific and can capture the differences in how bacteria function and contribute to diseases including cancer, while remaining general enough to detect these changes among different groups of individuals, populations, or countries.”

Using Machine Learning to Decode the Gut

The research required analyzing massive amounts of biological data. “As a bioinformatician, the challenge was to come up with an innovative approach for mass data analysis,” says Matija Trickovic, PhD student in Trajkovski’s lab and the study’s first author.

“We successfully developed the first comprehensive catalogue of human gut microbiota subspecies, together with a precise and efficient method to use it both for research and in the clinic.”

A Stool Test That Rivals Colonoscopy

By combining their bacterial catalogue with existing clinical datasets, the team built a model that can identify colorectal cancer using only stool samples. The results exceeded expectations.

“Although we were confident in our strategy, the results were striking,” says Matija Trickovic. “Our method detected 90% of cancer cases, a result very close to the 94% detection rate achieved by colonoscopies and better than all current non-invasive detection methods.”

With additional clinical data, the model could become even more accurate and eventually match colonoscopy performance. In practice, this type of test could be used for routine screening, with colonoscopies reserved for confirming positive cases.

Expanding Beyond Cancer Detection

A clinical trial is now being prepared in partnership with the Geneva University Hospitals (HUG) to better define which cancer stages and lesions the method can detect.

The implications extend far beyond colorectal cancer. By examining differences between subspecies within the same bacterial species, researchers can begin to uncover how gut microbes influence a wide range of health conditions.

“The same method could soon be used to develop non-invasive diagnostic tools for a wide range of diseases, all based on a single microbiota analysis,” concludes Mirko Trajkovski.

This balance matters because body composition plays a major role in long-term health. A higher proportion of fat mass (FM) is linked to a greater risk of death from obesity-related conditions, including cardiovascular problems. In contrast, a higher proportion of fat-free mass (FFM) is associated with a lower risk of death.

Why Fat Loss and Muscle Preservation Matter

The findings highlight an important tradeoff. While reducing fat is beneficial, maintaining lean mass is also critical for overall health and survival. Understanding how these two components change with different treatments remains an active area of research.

The researchers noted that more studies are needed to better understand how FM and FFM shift after bariatric surgery or treatment with GLP-1 receptor agonist drugs in real-world clinical settings. Their findings were published in JAMA Network Open.

Study Design and Patient Data

The study was led by Danxia Yu, PhD, associate professor of Medicine in the Division of Epidemiology, and Jason Samuels, MD, assistant professor of Surgery.

Researchers conducted a retrospective analysis using electronic health records. The study included 1,257 patients between the ages of 18 and 65 who underwent bariatric surgery at Vanderbilt Health from 2017 to 2022. It also included 1,809 patients treated with the drugs semaglutide or tirzepatide from 2018 to 2023.

Individuals with a history of end-stage renal disease or congestive heart failure were excluded from the analysis.

To evaluate changes in body composition, the researchers used bioelectrical impedance analysis. This method estimates FM and FFM based on individual characteristics such as height, weight, age, race, gender, history of diabetes, and duration of GLP-1 treatment.

Key Findings Over 24 Months

Over a 24-month period, both treatment approaches produced similar patterns. Patients experienced substantial reductions in FM along with modest decreases in FFM. At the same time, the ratio of FFM to FM increased, indicating an overall improvement in body composition.

The study also found differences between men and women. Male patients tended to preserve fat-free mass more effectively over the long term compared to female patients.

Research Team and Funding

The first authors of the study were graduate student Zicheng Wang, MS, and postdoctoral fellow Lei Wang, PhD, both in Epidemiology.

Additional contributors included Xinmeng Zhang and You Chen, PhD (Biomedical Informatics and Computer Science); Brandon Lowery (Vanderbilt Institute for Clinical and Translational Research); Lauren Lee Shaffer, MS, and Quinn Wells, MD (Cardiovascular Medicine); and Charles Flynn, PhD, Brandon Williams, MD, Matthew Spann, MD, and Gitanjali Srivastava, MD (Surgery).

The research was supported in part by National Institutes of Health grants R01DK126721 and R01CA275864.

Even with this long history, researchers have struggled to explain exactly how plant-based foods reduce inflammation. In laboratory settings, individual plant compounds often show anti-inflammatory effects, but usually only at levels far higher than what a normal diet can provide. This has led to doubts about whether so-called ‘anti-inflammatory foods’ can truly influence the immune system in real life. Another unresolved question is whether different compounds might work together inside cells, producing stronger effects in combination than on their own. Until recently, this type of synergy had rarely been tested or explained at the molecular level.

Study Explores How Plant Compounds Work Together

To better understand this, a team led by Professor Gen-ichiro Arimura from the Department of Biological Science and Technology at Tokyo University of Science, Japan, examined how combinations of plant-derived compounds affect inflammation in immune cells. Their findings, published in Volume 18, Issue 3 of the journal Nutrients, focused on compounds commonly found in mint, eucalyptus, and chili peppers. The researchers wanted to see whether pairing these compounds could reduce inflammatory signals more effectively than using them individually.

Testing Anti-Inflammatory Effects in Immune Cells

The team studied macrophages, immune cells that play a key role in inflammation by releasing signaling proteins called cytokines. These proteins help drive inflammatory responses. To simulate inflammation, the researchers exposed murine macrophages to lipopolysaccharide, a bacterial component often used in laboratory experiments. They then treated the cells with menthol (from mint), 1,8-cineole (from eucalyptus), capsaicin (from chili peppers), and β-eudesmol (from hops and gingers), testing each compound alone as well as in specific combinations.

Using gene expression analysis, protein measurements, and calcium imaging, the scientists tracked how these treatments affected important inflammatory markers. They also investigated whether the compounds acted through transient receptor potential (TRP) channels, which are proteins in the cell membrane that detect chemical and physical signals and regulate calcium activity linked to immune responses.

Powerful Synergy Between Common Food Compounds

When tested individually, capsaicin showed the strongest anti-inflammatory effect. However, the most striking results appeared when compounds were combined. “When capsaicin and menthol or 1,8-cineole were used together, their anti-inflammatory effect increased several hundred-fold compared to when each compound was used alone,” highlights Prof. Arimura.

Further experiments helped clarify how this synergy works. Menthol and 1,8-cineole influenced inflammation through TRP channels and calcium signaling. Capsaicin, on the other hand, appears to act through a different pathway that does not rely on TRP channels. “We demonstrated that this synergistic effect is not a coincidence, but is based on a novel mode of action resulting from the simultaneous activation of different intracellular signaling pathways,” says Prof. Arimura. “This provides clear molecular-level evidence for the empirically known effects of combining food ingredients.”

What This Means for Diet and Future Health Products

These results suggest that mixtures of plant compounds can produce meaningful biological effects even at the lower levels typically consumed in a normal diet. The findings also point to new opportunities for developing functional foods, dietary supplements, seasonings, or even fragrances that deliver stronger benefits using smaller amounts of active ingredients.

More broadly, the research supports the idea that the health benefits of plant-rich diets may come not from individual ‘super compounds,’ but from the way many compounds interact and reinforce each other.

A Step Toward Understanding Food and Inflammation

Although additional studies in animals and humans are needed to confirm these effects, this work provides a clearer explanation of how everyday foods and natural compounds may help regulate chronic inflammation. Over time, this could play an important role in supporting long-term health.

About Professor Gen-ichiro Arimura from Tokyo University of Science

Dr. Gen-ichiro Arimura is a Professor in the Department of Biological Science and Technology at Tokyo University of Science, Japan. Prof. Arimura earned his Ph.D. degree in 1998 from Hiroshima University Graduate School. His research focuses on biological communications, plant biotechnology, and plant ecology. Since 1996, he has published 130 peer-reviewed papers with more than 6,600 citations. He also holds four patents and received an award from the International Society of Chemical Ecology in 2023.

Funding information

This work was partially supported by Japan Society for the Promotion of Science (JSPS) KAKENHI (24K01723) and Tokyo University of Science Research Grants.

Researchers at Flinders University have now developed a promising new approach that could help remove some of the hardest-to-capture forms of these long-lasting pollutants from water.

New Method Targets Hard-to-Remove PFAS

The team, led by Flinders ARC Research Fellow Dr. Witold Bloch, created specialized materials known as adsorbents that can effectively capture PFAS. Their method is particularly successful at trapping short-chain PFAS, which are notoriously difficult to remove with current water treatment technologies.

Their findings, published in the journal Angewandte Chemie International Edition, highlight the use of a nano-sized molecular cage designed to act as a highly selective ‘PFAS trap’.

“While some long-chain PFAS can be partially removed using existing water treatment technologies, the capture of short-chain PFAS — which are more mobile in water — remains a major unresolved challenge,” says project leader Dr. Witold Bloch, from Flinders University’s College of Science and Engineering.

“We discovered that a nano-sized cage captures short-chain PFAS by forcing them to aggregate favourably inside its cavity. This unusually strong binding mechanism is different from that of traditional adsorbent materials.”

How the Nano Cage Technology Works

To make the system effective, the researchers embedded these molecular cages into mesoporous silica, a material that typically does not bind PFAS on its own.

First author Caroline Andersson, a PhD candidate in chemistry at Flinders University, explains that adding the nanosized cage allows the material to remove a wide range of PFAS compounds from water, including those that are especially difficult to isolate.

“The most exciting aspect of this project was that we first conducted in-depth studies of how PFAS bind within the cage on the molecular level,” she says. “That allowed us to understand the precise binding behaviour and then use that knowledge to design an effective adsorbent for PFAS removal.”

High Efficiency and Reusability in Water Filtration

Laboratory tests showed that the new material can remove up to 98% of PFAS at environmentally relevant concentrations in model tap water.

“The adsorbent also demonstrated reusability, remaining highly effective after at least five cycles of reuse. These results highlight its potential for integration into water filtration systems for polishing drinking water at the final stage of treatment,” adds Dr. Bloch.

“This research represents an important step toward the development of advanced materials capable of tackling one of the world’s most persistent environmental contaminants,” he concludes.

Growing Concern Over PFAS Pollution

PFAS chemicals are widely used in industrial manufacturing, aviation firefighting foam, and everyday consumer products. Over time, they can enter freshwater and marine environments, raising increasing concerns about potential health risks to humans, livestock, and wildlife.

Acknowledgements: The PFAS study was funded by Australian Research Council grants (FT240100330, DE240100664, DP230100587, CE230100021 and FT220100054), and Playford Trust PhD and ATSE Elevate PhD scholarships. The study used facilities including the MX1 and MX2 beamline at the ANSTO Australian Synchrotron, Australian Cancer Research Foundation detector, Flinders Analytical, Flinders Deepthought and the National Facility of the National Computational Infrastructure, and Microscopy Australia, enabled by NCRIS and the government of South Australia at Flinders Microscopy and Microanalysis.